Sofinnova Partners, in collaboration with cancer center Gustave Roussy, created Signadori Bio, a novel cell therapy platform.
Matthieu Coutet, Partner at Sofinnova Partners, is the CEO of the company.
Developed with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, Signadori Bio has developed a cell therapy platform focused on improving cancer treatment. Since the partnership’s inception in 2023, it has rigorously evaluated 50 promising projects. This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. More information will be released as the company comes out of stealth later this year. Additionally, several other promising projects are in the pipeline, showcasing the immense potential for future breakthroughs in cancer therapeutics.
FinSMEs
19/03/2025